https://www.selleckchem.com/pr....oducts/Cediranib.htm
BACKGROUND We aimed to explore the predictive value of radiomics signature for the recurrence-free survival (RFS) in patients with resected stage I non-small-cell lung cancer (NSCLC). METHODS From January 2009 to December 2011, patients with resected stage I NSCLC were divided into sub-solid and pure-solid groups according to presence of ground glass opacity (GGO) in computed tomography (CT). A total of 107 extracted radiomics features were reduced to 8 features by using LASSO-Cox analysis to develop a radiomics signature for RFS pred
Like
Comment
Share
